Summit Therapeutics (SMMT) executive compensation, 2026 proxy

Mahkam Zanganeh, Co-Chief Executive Officer, President and Director, was paid $246M in 2025. The CEO-to-median-employee pay ratio was 489:1, on median employee pay of $503,340.

Filed
April 17, 2026
Annual meeting
June 10, 2026
Pay year
2025
Named executives
3
CEO total pay
$246M2025
CEO to median employee
489:1median $503,340
Prior say-on-pay support
97%of votes cast
CEO Pay Ratio
489:1Based on SEC required calculation
Median Employee Pay
$503,340Annual total compensation
Bonus Achievement
105%Based on 2025 OKR performance
Say-on-Pay Support
97%Support at 2025 annual meeting

How Zanganeh was paid

$246M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary0%Bonus0%Option awards100%All other compensation0%

Named executive officers

ExecutiveTotal
Robert W. DugganCo-Chief Executive Officer and Chairman$172,376
Mahkam ZanganehCo-Chief Executive Officer, President and Director$246,047,279
Manmeet SoniChief Operating Officer, Chief Financial Officer and Director$249,127,782

What changed and why

  • $246MMahkam Zanganeh received total compensation of $246,047,279 for fiscal year 2025 driven by option award modifications.
  • Robert W. Duggan declined any compensation for his role as Co-CEO.
  • $249.1MManmeet Soni received total compensation of $249,127,782 for fiscal year 2025.
  • 105%The Company exceeded all OKRs for 2025 resulting in a business achievement level of 105%.
  • 97%Stockholders approved the previous say-on-pay proposal with approximately 97% support.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.